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ABSTRACT 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting long-term secondary complication. Aldose reductase, the 
rate-limiting enzyme of the polyol pathway, plays a key role in the treatment of diabetic complications. Appropriately, inhibition of this enzyme 
is emerging as a major therapeutic strategy for the pathogenesis of secondary complication. In this study, we describe a series of 5 aryl 
benzylidene -thiazolidine, 4-dione derivatives, F3 synthesized as aldose reductase inhibitors. Besides inhibiting efficiently the target enzyme, F4 
and F5 showed additional AR inhibitory as well as hypoglycaemic activity (146.15 and 175.20 mg/dl ) thus emerging as novel dual acting 
compounds. The bezylidene derivative F3, the most promising of the whole series, showed a well-balanced, consisting of ALR2 inhibitory efficacy 
(83.00% at 10µg/mL), similarly, F3 have lower blood glucose level in the range of 131.11 mg/dl at 15 mg/kg body weight. This compound show 
robust in vitro and in vivo efficacy, and could be considered as promising dual target antidiabetic drug candidates. 
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Introduction 
Diabetes is a devastating disease increasing rapidly all over 
the world, epidemiological studies have estimated at over 
171 million people worldwide were suffering with this 
disease in 2000 and the prevalence is expected to grow more 
than twice and reach to 366 million by 2030.1 Although, 
diabetic patients in China have reached 92 million in 2007, 
and even escalate to 114 million in 2010.2,3  
The increase in prevalence rate are as a result of 
authorization, westernization and their associated lifestyle 
changes, increase in life expectancy at birth, obesity, physical 
inactivity, and possibly a genetic predisposition. 
Diabetes mellitus is a metabolic disorder characterized by 
hyperglycemia resulting long-term complications, such as 
neuropathy, nephropathy, cataracts, retinopathy due to 
defects in insulin action, insulin secretion or both. 
Aldose reductase (ALR2; EC: 1.1.1.21) plays a pivotal role in 
development of chronic diabetic complications, belongs to 
aldoketo reductases super family. It is the first rate limiting 
enzyme in polyol pathway and reduces glucose to sorbitol by 
utilizing NADPH as a cofactor. Sorbitol dehydrogenase is the 
enzyme responsible for the conversion of sorbitol into 
fructose.  
Generally, ALR2 has a low activity and only a small amount 
of the glucose is metabolized by polyol pathway. In 
hyperglycemia, however, ALR2 is activated and one third of 
the total metabolic glucose turns to the alternative polyol 
pathway, which leads to the accumulation of sorbitol in 
tissues possessing insulin-independent uptake of glucose, 
such as kidney, lens, retina, peripheral nerves.4 
Sorbitol is hardly excreted across cell membranes due to 
strong polarity, and therefore its intracellular accumulation 
would lead to osmotic imbalance, cell swelling, and changes 
of membrane permeability, mainly in lens. Also, the 
abnormal level of NADPH and NAD+ caused by the polyol 
pathway would induce modification in cellular redox 
potentials, and unconventionally activated enzymes such as 
nitric oxide synthase (NOS) and glutathione reductase would 
give rise to the cellular oxidative stress. As a consequence, 
the imbalance between increased production of radical 
oxygen species (ROS) and reduced intracellular antioxidant 
defense occurs.5  
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In the recent few years, the aromatic heterocyclic structures 
including thiazolidenedione, benzamide and other 
derivatives have been found to be excellent scaffold for the 
ARI drug design, which led to a number of novel and potent 
inhibitors as promising drug candidates for the treatment of 
diabetic complications. 
Heterocyclic compounds are an important part of the 
synthetic medicinal chemistry. They offer a high degree of 
structural variety and have proven to be widely useful as 
therapeutic agents. Heterocyclic compounds play an 
important role in the biological processes. They are 
widespread as natural products. Heterocycles have huge 
potential as the most promising molecules as lead structures 
for the design of new drugs.6 
Rhodanine is a five-membered heterocyclic molecule 
containing a thiazole nucleus with thioxo group on second 
carbon and carbonyl group on fourth carbon. Structural 
modifications of rhodanine derivatives consequently, 
compounds with a broad spectrum of pharmacological 
activities. 7, 8 
Rhodanine is a five-membered heterocycle containing thio 
ether and amino groups at positions 1 and 3, respectively. It 
is structurally related to thiazolidine-2,4-dione and 2-
iminothiazolidine-4-one that include an oxo or imino group, 
respectively, instead of the thioxo group at position 2. It is 
also related to 4-thioxothiazolidin-2-one, which bears oxo 
and thioxo groups at positions opposite to those in 
rhodanine. However these heterocycles reveal to be very 
similar at first gaze, compounds derivatives based on these 
framework usually differ in their biological activities. The 
rhodanine ring allow the formation of several types of ligand 
protein interaction with the amino acid residues like in 
hydrogen bonds, a hydrogen bond acceptor or donor, 
hydrophobic and p–p and cation–p interactions with amino 
acids with aromatic or charged side chains in the case of 
aromatic 5-benzylidene rhodanines. All these possibilities 
give the rhodanine framework special properties to 
compounds possessing high biological activity.9-15 
There are currently two main classes of AR inhibitors, cyclic 
imides such as sorbinil and carboxcylic acid derivatives such 
as tolrestat and epalrestat, is only drug marketed to treat the 
diabetes complications. 
Although a large no of synthetic ARIs have shown to inhibit 
the enzyme and have been tested in clinical trials, the clinical 
efficacy of these compounds is not satisfactory and some 
have also shown deleterious side effect.16 Furthermore 
recent study was explored to improving the activity via 
heterocyclic analogues like Thiazolidinediones and 
Benzimidazole  rhodanine  derivatives which improve 
glycaemic control type 2 diabetes now as effective 
antihyperglycaemic agents and  AR inhibitors 
Consequently it is need to develop new analogues of aldose 
reductase inhibitors which could be devoid from the toxicity. 
In this study, we have determined the probable inhibitory 
effects of some rhodanine derivatives, already known to 
have antidiabetic activities but their effectiveness generally 
decreases in vivo, probably due to their poor penetrability to 
key target tissues, in particular, peripheral nerves. Hence, 
the aim of this work to develop new ARIs, active on relevant 
targets involved in the control of glucose level to 
hyperglycaemic conditions, are presented as promising 
antidiabetic compounds.   
At present study, some new analogs of 5-arylidene-2, 4-
dioxothiazolidines were synthesized and biological 
evaluated as potent ARI such as imine derivatives of 
rhodanine possess anti diabetes properties. 
Material and Methods  
Chemistry  
All the chemicals and reagents used in the synthesis of 
designed compounds were of synthetic grade, and 
commercially procured from Loba, Highmedia, and E. Merck. 
The melting points were determined using open capillary 
tubes and are uncorrected. Purity of the all synthesized 
compounds was checked by thin layer chromatography 
technique (0.2 mm thickness of silica gel G plates) and iodine 
was used as visualizing agent and recrystallize with column 
chromatography technique. For the purpose of 
chromatography glass column (high 18″ with internal 
diameter 20 mm), column grade silica gel mesh #240-400 as 
the stationary phase and appropriate solvent system as 
mobile phase were used. Absorption maxima (λmax) of the 
intermediate and synthesized compounds were determined 
on Shimadzu 1800 UV-visual © 2018 spectrophotometer by 
scanning the compound IR spectra were recorded on 
Shimadzu8400s at BR Nahata college of Pharmacy, Mandsaur 
(M.P.). The samples for NMR and Mass were tested at IIT 
Indore (M.P.). 
In-vitro biological evaluation 
Enzyme preparation14. 
Eye ball was removed from goat immediately after sacrifice 
and stored in ice-cold container. Lenses were removed by 
lateral incision of the eye, washed with ice-cold distilled 
water and kept cold. The lenses were homogenized in 10 
volumes of 100 mM ice- cold potassium phosphate buffer, 
pH6.2 and centrifuged at 15,000 xg for 30 minutes at 40C. 
The resulting supernatant was used as the source of aldose 
reductase. Saturated ammonium sulphate (100%) was 
added to the supernatant from the homogenate to reach 40% 
saturation and then allowed to stand for 15 min with 
occasional stirring to ensure the completeness of 
precipitation. It was then centrifuged and the precipitate was 
discarded. The same procedure was repeated for the 
resulting supernatant using 50% and 75% ammonium 
sulphate saturations. The final supernatant was used as the 
partially purified aldose reductase. The precipitate recovered 
from the 75% saturated fraction, possessing ALR2 activity, 
was Redissolved in 0.05 M NaCl and dialyzed overnight in 
0.05 M NaCl. The dialyzed material was used for the 
enzymatic assay.  
 
In-vitro Enzyme inhibition assay of aldose reductase 
ALR2 activity has been assayed at 30°C in a reaction mixture 
containing 0.75 mL of 10 mM D,L-glyceraldehyde, 0.5 ml of 
0.104 mM NADPH, 0.75 mL of 0.1 M sodium phosphate 
buffer (pH=6.2), 0.3 mL of enzyme extract and 0.7 mL of 
deionized water in a total volume of 3 ml. All the above 
reagents, except D, L-glyceraldehyde, were incubated at 30°C 
for 10 minutes; then substrate was added to start the 
reaction, which was monitored for 5 minutes. Enzyme 
activity calibrated by dilutes the enzymatic solution to obtain 
an average reaction rate of 0.011±0.0010 absorbance 
units/minute for the sample. AR percentage inhibitory 
activity of the synthesized compounds (15 µL, 5µg/mL) has 
been determined using same procedure. 
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In-vivo Biological Evaluation  
Alloxan Induced Diabetic Model 
The diabetes in Wister rats (150 ± 20 g) was experimentally 
induced by intra peritoneal administration of alloxan 
monohydrate (dose 120 mg/kg body weight) in saline (1% 
w/v NaCl). Prior to this rat were fasted for 18 h but were 
allowed free access to drinking water. The rats were kept for 
next 24 h on 5% glucose solution in bottles in their cages to 
prevent hypoglycemia. The blood glucose level was checked 
after 72 h. Animals with serum glucose levels 200–350 
mg/dl were considered diabetic and were used for the study. 
A 5% dextrose solution was given in feeding bottle for a day 
to overcome the early hypoglycemic phase. The blood 
glucose regulator has been monitored after alloxination by 
withdrawing a drop of blood from the tail vein by Tail 
tipping method. The blood dropped on the dextrostix 
reagent pad. The strip was inserted into microprocessor 
digital blood glucometer and readings were noted. 
Experimental Anti diabetic Evaluation 
Experimental Animals Adult Wister rats weighing (120–150 
g) of either sex were used as experimental animals. All the 
animals were housed in cage at a temperature of 22 ±1C and 
a relative humidity of 55± 5%and 12 h dark and 12 h light 
cycle was followed during the experiments. Animals were 
allowed free access to food and water ad libitum. During the 
study period, guidelines of Committee for the Purpose of 
Control and Supervision of Experiments on Animals 
(CPCSEA) were followed and experimental study has been 
approved by Institutional Animal Ethical Committee (IAEC), 
Protocol no. is PBRI/IAEC/PN-17049a. 
Experimental Design  
Experimental design Animals were divided into 6 rats in 
each group. The animals found diabetic after induction of 
alloxan monohydydrate have been selected for the further 
study. Group 1 for diabetic control (Alloxan induced), Group 
2 for reference standard (rosiglitazone 4 mg/kg) and Group 
3-8 for synthesized compounds (15 mg/kg for acute study). 
Antidiabetic activities of the synthesized compounds were 
tested by using alloxan induced diabetic model in Wistar 
rats. The dose of the synthesized compounds (15 mg/kg 
body weight) and rosiglitazone (4 mg/kg body weight) were 
administered orally in 2% acacia. The blood glucose level 
was monitored at different times 0, 1, 3, and 9 hours 
respectively. 
GENERAL SYNTHESIS AND SCHEME 
Synthesis of following compounds is shown 
1. Method for the Synthesis of 2-thiaoxozolidin-4- one 
nitro benzylidene derivatives (C) 
2. Method for the Synthesis of 2-thiaoxozolidin-4- 
oneamino benzyl derivatives (D) 
3. Method for the Synthesis of substituted benzylidene 2,4-
dioxothiazolidin derivatives (F1-F5) 
4. Methods for the Synthesis (Z)-N-(4-((4-oxo-2-
thioxothiazolidin-5-ylidene)methyl) phenyl)benzamide 
F6
 
NO2OHC +
S
NH
O
S
H2N
NH
S
S
O
O2N
NH
S
S
O
A
a
b
B C
D  
Reagents conditions: (a) CH3COONa, CH3COOH, Reflux; (b) Tin granules, HCl, Heat, NaoH;  
Scheme1: General synthesis scheme of 2-thiaoxozolidin-4- one benzylidene derivatives. 
 
Method for the Synthesis of 2-thiaoxozolidin-4- one nitro 
benzylidene derivatives (C) 
Equimolar concentration of derivative of 4 nitro 
benzaldehyde (0.025 mol) and rhodanine (0.025 mol) was 
taken in round bottom flask containing glacial acetic acid. To 
this, catalytic amount (0.080gm) was added the reaction 
mixture was stirred and heated at 100-105 ºC for 10 -12 hrs. 
Progress of the reaction mixture was checked through TLC. 
After completion of reaction, mixture was kept aside for 
overnight at RT crystalline product was filtered, washed with 
cold acetic acid and used in next step. 
 
NO2OHC +
S
NH
O
S
O2N
NH
S
S
O
A
a
B
C
 
Reagent condition: a=CH3COOH, heat and stir 
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Method for the Synthesis of 5 aryl (amino benzylidene)-
2-thioxothiazolidin-4-one (D): The crude amount C (0.025 
mol) and granulated tin (0.038 mol) were taken in RBF 
equipped with reflux condenser. 10 ml HCl was added in step 
to control vigorous reaction. After complete addition of HCl, 
the reaction mixture was heated on water bath and progress 
of the reaction mixture was checked through TLC. After 
completion of reaction gradually sodium hydroxide solution 
(7.5gm in 12 ml) was added and amine was separated out.
 
H2N
NH
S
S
O
b
D
O2N
NH
S
S
O
C  
Reagent condition: b= granulated tin, HCl and heat 
Synthesis of 5 aryl (amino benzylidene)-2-thioxothiazolidin-4-one (D) 
 
Method for the of substituted 5 aryl (amino 
benzylidene)-2-thioxothiazolidin-4-one: Equimolar 
concentration of compound (D) and substituted 
benzaldehyde reflux with ethanol (3.5ml), and acetic acid (2-
3drop).The reaction mixture was stirred and heated at 100-
105 ºC for 4 hrs. Progress of the reaction mixture was 
checked through TLC. After completion of reaction, product 
was filtered and washed. 
 
c
N
H
N
S
S
O
H
R
H2N
NH
S
S
O
D
+ H
O
R
F1-F5E
 
Reagent condition: c= ethanol, acetic acid, heat and stirring 
Scheme 2: Synthesis scheme of substituted 5 aryl (amino benzylidene)-2-thioxothiazolidin-4-one 
 
Synthesis of benzoyl chloride  
Benzoic acid (0.01 mol) was refluxed with thionyl chloride 
for 3-4 hrs, and the reaction was monitored through TLC. 
After completion of reaction, evaporate excess of thionyl 
chloride under reduced pressure, and the crude solid was 
used as such in next step. 
 
C
O
OH
d
C
O
Cl
E
F
 
Reagents and conditions: (d) SOCl2, Reflux 
 
Method for the synthesis of N(Z)-N-(4-((4-oxo-2-
thioxothiazolidin-5-ylidene)methyl)phenyl) benzamide 
F6: crude product was taken in RBF containing anhydrous 
dichloromethane. To this, a catalytic amount of triethylamine 
(0.001) was added. To the reaction mixture benzoyl chloride 
was added slowly with constant stirring. Progress of the 
reaction mixture was checked though TLC. After evaporation 
of the solvent under reduced pressure, the crude solid was 
purified by column chromatography. 
 
S
HN
S
O
H
N
C
O
Cl
O
H2N
NH
S
S
O
+
e
FTf F6
 
Reagents and conditions: (d) CH2Cl2, N(CH2CH3)3,C6H5Cl and reflux 
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RESULT AND DISCUSSION 
A series of rhodanine derivatives were synthesized. The structures of these compounds were established by means of IR, 1H 
NMR, and elemental analysis study shown in table. 
Table 1: IR, NMR and mass studied of synthesized compound 
 
Characterization of synthesized rhodanine compounds 
Table 2: λmax, , Rf, MW, % yield of synthesized compound 
Comp no. R MW %Yield Rf value λmax(nm) in Methanol 
F1 
O
H
 
250–255ºC 60.0 0.59 352 
F2 
OH
NO2
 
240–243ºC 35.5 0.52 359 
F3 OH
NO2  
230–235ºC 55.0 0.79 368 
F4 OH
NO2  
225–228ºC 60.2 0.75 370 
F5 O
N
H3C
H3C
 
200-210ºC 79.8 0.48 338 
F6 
O
Cl
 
220-223ºC 33.4 0.59 358 
 
Aldose reductase Inhibitory activity 
 All the synthesized 5 aryl 2-thioxothiazolidin-4-one 
derivatives were evaluated for their ability to inhibit the in 
 
vitro reduction of D, L glyceraldehydes by partially purified 
ALR from goat lenses; sorbinil was used as a reference drug 
(Table 3 and Fig 1) 
1  IR (KBr, cm-1)3591(N-H), 3016(C-H), 1867 (C=O), 1651 
(C=C), 1560(C=N);1H NMR (400 MHz, DMSO) δ 10.95 (s, 
1H), 8.81 (s, 1H), 7.75 – 7.61 (m, 2H), 7.37 (d, J = 5.9 Hz, 
2H), 7.33 – 7.13 (m, 6H). m/e: 324.04; C, 62.94; H, 3.73; 
N, 8.63; O, 4.93; S, 19.77  
2  IR (KBr, cm-1)3280(N-H), 3155(C-H), 1722(C=O), 1721 
(C=C), 1207(C=N)1H NMR (500 MHz, DMSO) δ 8.66 (s, 
1H), 7.97 (s, 1H), 7.61 – 7.52 (m, 3H), 7.50 (s, 1H), 7.41 
(s, 1H), 7.32 – 7.18 (m, 2H), 7.16 (s, 1H).m/e: 369.02 ;C, 
55.27; H, 3.00; N, 11.37; O, 12.99; S, 17.36  
3  IR (KBr, cm-1)3340(N-H), 3100(C-H), 1842(C=O), 1629  
(C=C), 1157(C=N);1H NMR (400 MHz, DMSO) δ 10.96 (s, 
1H), 8.82 (s, 1H), 8.62 (s, 1H), 8.27 (s, 1H), 8.04 (s, 1H), 
7.55 (s, 1H), 7.34 – 7.23 (m, 5H).  m/e: 369.02 ;C, 55.27; 
H, 3.00; N, 11.37; O, 12.99; S, 17.36  
4  IR (KBr, cm-1)3201(N-H), 3051(C-H), 1867 (C=O), 1452 
(C=C), 1639(C=N);
1
H NMR (400 MHz, DMSO) δ 10.97 (s, 
1H), 8.70 (s, 1H), 8.11 – 7.93 (m, 2H), 7.87 – 7.70 (m, 
2H), 7.39 – 7.19 (m, 5H). m/e: 369.02 ;C, 55.27; H, 3.00; 
N, 11.37; O, 12.99; S, 17.36  
5  IR (KBr, cm-1)3340(N-H), 3100(C-H), 1842(C=O), 1629  
(C=C), 1157(C=N);1H NMR (400 MHz, DMSO)  δ 9.97 (s, 
3H), 7.89 – 7.75 (m, 6H), 7.47 – 7.31 (m, 19H), 7.31 (s, 
2H), 7.13 (s, 3H).m/e: 369.02 ;C, 55.27; H, 3.00; N, 
11.37; O, 12.99; S, 17.36 
6 
N NH
S
S
O
N
CH3H3C  
IR (KBr, cm-1)3379(N-H), 2808(C-H), 1869(C=O), 
1541(C=C), 1689(C=N); 1H NMR (400 MHz, DMSO) δ 
10.98 (s, 1H), 8.81 (s, 1H), 7.34 – 7.19 (m, 5H), 7.08 (d, J 
= 11.7 Hz, 2H), 7.01 (s, 1H), 6.67 (s, 1H), 2.91 – 2.86 (m, 
6H). m/e: C, 62.10; H, 4.66; N, 11.43; O, 4.35; S, 17.45 
N
NH
S
S
O
O2N
N NH
S
S
O
NO2
N NH
S
S
O
N
NH
S
S
O
NO2
N
H
NH
S
S
O
O
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Table 3: Aldose reductase percentage inhibitory activity of synthesized 5 aryl benzylidene 2-thioxothiazolidin-4-one 
S.N. Comp Code % Inhibition 
1 Standard (Sorbinil) 70.2 
2 F1 65.05 
3 F2 29.00 
4 F3 83.14 
5 F4 76.51 
6 F5 72.32 
7 F6 57.13 
 
 
Figure 1: Graphical representation of aldose reductase inhibitory activity of 5 aryl benzylidene 2-thioxothiazolidin-4-
one 
 
Figure 2: Graphical representation of antidiabetic activity of 5 aryl benzylidene 2 thioxothiazolidin-4-one 
Antidiabetic activity 
In vivo biological evaluation of all the synthesized rhodanine also evaluated for their antidiabetic activity using rosiglitazone as 
reference drug. The decrease in blood glucose level against each compound is shown in Table 3 and Fig. 3.  
Table 4: Antidiabetic activities of the synthesized 5arylbenzylidene 2, thioxothiazolidin-4-one 
Comp 
code 
Decrease in blood glucose level mg/dl 
0 hrs 1 hrs 3 hrs 6 hrs 9 hrs 
Cntrol 75.20±1.306 77.25±1.120 78.50±1.478 80.32±1.789 85.20±1.200 
Std(rosiglitazo) 283.35±1.250*** 190.25±2.220** 181.45±2.120** 155.20±1.230*** 135.35±1.185*** 
F1 286.51±2.520** 215.31±2.250** 199.35±2.325** 170.38±3.322* 163.30±1.340*** 
F2 283.16±2.355** 240.50±1.320*** 196.00±4.300* 165.20±1.255*** 154.30±2.270** 
F3 282.15±1.410*** 194.15±1.230*** 177.12±1.220*** 154.17±1.300*** 131.11±1.150*** 
F4 284.15±1.400** 199.15±1.235*** 184.22±1.225*** 165.26±2.325** 146.15±1.280*** 
F5 285.24±2.420** 210.15±1.250*** 182.22±2.330** 158.00±3.320* 175.20±1.300*** 
F6 285.24±2.420** 209.15±1.250*** 180.22±2.330** 154.00±3.320* 170.20±1.300*** 
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CONCLUSION 
The present work was studied on 5 aryl benzylidene -
thiazolidine, 4-dione derivatives, this family constitutes a 
scaffold from which more potent dual acting (aldose 
reductase inhibitory action and antihyperglycemic action) 
compounds could be designed by acting on ALR2. In the 
present case compound F3 may show good aldose reductase 
inhibitory action but optimum antihyperglycemic action, that 
most of the electron-withdrawing substituents in the 
aromatic aldehydes can stabilize the creation of stable 
iminium ion. Moreover, F4 and F5 both the actions were 
good and have been optimized. All significant scaffold of 
compound increased the interaction of the inhibitor with the 
hydrophobic region of the ALR2 active pocket with these 
targets. It is explore that rhodanine derivatives gives 
potential dual action but significant in aldose inhibitory 
activity. It is evident from the present study that rhodanine 
may be considered as a new class of potent and selective 
inhibitors of ALR2. The compounds can be further modified 
to get promising ALR2 inhibitors for the prevention and 
treatment of diabetic complications.  
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